Sinphar apologizes for drugs with quality problemsSELF-REGULATING: Sinphar last week examined all of its drug lines after the FDA found in July that six of its drugs had potency issues. The agency demanded that Sinphar stop selling the six and recall them, to safeguard the interests of consumers. The company found that another 17 drugs had less than 90 percent of their labeled potency and would recall them, Lou said. The reduction of the drugs’ potency could be attributed to the manner in which they are packaged, as the firm packaged some of its ointments in plastic bottles instead of aluminum tubes, making it easier for the chemicals to evaporate, she said. Meanwhile, some drugs’ potency weakens due to improper storage methods, the firm said.

Source: Taipei Times October 07, 2020 15:56 UTC